• Translating the
    Library of Life
    into transformative therapeutics.

    Read more

  • Learning from the
    Memory of Life
    to develop truly novel therapies.

    Read more

  • Neurimmune’s anti-alpha-
    synuclein antibody
    program for Parkinson in Phase 2.

    Read more

  • Neurimmune's anti-SOD1
    antibody program for ALS
    in Phase 1. Read more


Neurimmune is a biopharmaceutical company translating human immune memory into transformative therapeutics.

Neurimmune’s pipeline comprises drug candidates for Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, fronto-temporal dementia, dementia with Lewy bodies as well as cardiomyopathy and type 2 diabetes.

With its Reverse Translational Medicine™ technology platform, Neurimmune translates the genetic information obtained from white blood cells from elderly human donors into therapeutic antibodies.